Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics
PTPI Price/Volume Stats
| Current price | $0.68 | 52-week high | $9.54 |
| Prev. close | $0.78 | 52-week low | $0.66 |
| Day low | $0.66 | Volume | 1,843,982 |
| Day high | $0.90 | Avg. volume | 1,012,544 |
| 50-day MA | $1.36 | Dividend yield | N/A |
| 200-day MA | $1.81 | Market Cap | 4.68M |
PTPI Stock Price Chart Interactive Chart >
Petros Pharmaceuticals Inc. (PTPI) Company Bio
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Latest PTPI News From Around the Web
Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in discussions with third-party technology partnersNEW YORK, ... |
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAImportant step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding ... |
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelCompany well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication ... |
Petros Pharmaceuticals to Present at the LD Micro Main Event XVINEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief ... |
Petros Pharmaceuticals Provides Letter to ShareholdersPetros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders: |
PTPI Price Returns
| 1-mo | -55.26% |
| 3-mo | -42.86% |
| 6-mo | -56.13% |
| 1-year | -82.38% |
| 3-year | -97.85% |
| 5-year | N/A |
| YTD | -51.77% |
| 2023 | -39.48% |
| 2022 | -93.00% |
| 2021 | -24.32% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...